• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

移植前标准在预测肝细胞癌进展和等待名单退出方面的表现。

Performance of pre-transplant criteria in prediction of hepatocellular carcinoma progression and waitlist dropout.

机构信息

Latin American Liver Research Educational and Awareness Network (LALREAN), Buenos Aires, Argentina.

Hospital Universitario Austral, University, School of Medicine, Buenos Aires, Argentina.

出版信息

Liver Int. 2022 Aug;42(8):1879-1890. doi: 10.1111/liv.15223. Epub 2022 Apr 2.

DOI:10.1111/liv.15223
PMID:35304813
Abstract

BACKGROUND & AIM: Liver transplantation (LT) selection models for hepatocellular carcinoma (HCC) have not been proposed to predict waitlist dropout because of tumour progression. The aim of this study was to compare the alpha-foetoprotein (AFP) model and other pre-LT models in their prediction of HCC dropout.

METHODS

A multicentre cohort study was conducted in 20 Latin American transplant centres, including 994 listed patients for LT with HCC from 2012 to 2018. Longitudinal tumour characteristics, and patterns of progression were recorded at time of listing, after treatments and at last follow-up over the waitlist period. Competing risk regression models were performed, and model's discrimination was compared estimating Harrell's adapted c-statistics.

RESULTS

HCC dropout rate was significantly higher in patients beyond (24% [95% CI 16-28]) compared to those within Milan criteria (8% [95% IC 5%-12%]; p < .0001), with a SHR of 3.01 [95% CI 2.03-4.47]), adjusted for waiting list time and bridging therapies (c-index 0.63 [95% CI 0.57; 0.69). HCC dropout rates were higher in patients with AFP scores >2 (adjusted SHR of 3.17 [CI 2.13-4.71]), c-index of 0.71 (95% CI 0.65-0.77; p = .09 vs Milan). Similar discrimination power for HCC dropout was observed between the AFP score and the Metroticket 2.0 model. In patients within Milan, an AFP score >2 points discriminated two populations with a higher risk of HCC dropout (SHR 1.68 [95% CI 1.08-2.61]).

CONCLUSIONS

Pre-transplant selection models similarly predicted HCC dropout. However, the AFP model can discriminate a higher risk of dropout among patients within Milan criteria.

摘要

背景与目的

由于肿瘤进展,尚无用于预测肝癌(HCC)肝移植(LT)候选者脱落的 HCC 筛选模型。本研究旨在比较甲胎蛋白(AFP)模型和其他 LT 前模型在预测 HCC 脱落方面的表现。

方法

本研究为一项多中心队列研究,纳入了 2012 年至 2018 年间拉丁美洲 20 家移植中心的 994 例 HCC 患者。在等待名单期间,记录患者 LT 时、治疗后和最后一次随访时的肿瘤纵向特征和进展模式。使用竞争风险回归模型,通过估计哈雷尔调整后的 C 统计量比较模型的判别能力。

结果

超出米兰标准的 HCC 患者(24% [95%CI 16-28])比符合米兰标准的 HCC 患者(8% [95%CI 5%-12%];p<0.0001)的 HCC 脱落率显著更高,校正等待时间和桥接治疗后,调整风险比(SHR)为 3.01 [95%CI 2.03-4.47]),校正后 C 指数为 0.63 [95%CI 0.57; 0.69])。AFP 评分>2 的患者 HCC 脱落率更高(校正 SHR 为 3.17 [95%CI 2.13-4.71]),C 指数为 0.71(95%CI 0.65-0.77;p=0.09 与米兰标准相比)。AFP 评分和 Metroticket 2.0 模型在 HCC 脱落的判别能力相似。在符合米兰标准的患者中,AFP 评分>2 分可区分 HCC 脱落风险较高的两组人群(SHR 为 1.68 [95%CI 1.08-2.61])。

结论

LT 前筛选模型可预测 HCC 脱落。然而,AFP 模型可在符合米兰标准的患者中预测 HCC 脱落的高风险。

相似文献

1
Performance of pre-transplant criteria in prediction of hepatocellular carcinoma progression and waitlist dropout.移植前标准在预测肝细胞癌进展和等待名单退出方面的表现。
Liver Int. 2022 Aug;42(8):1879-1890. doi: 10.1111/liv.15223. Epub 2022 Apr 2.
2
A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.一种用于肝细胞癌的新的候补者退出评分 - 确定一个可预测移植后生存状况更差的阈值。
J Hepatol. 2021 Apr;74(4):829-837. doi: 10.1016/j.jhep.2020.10.033. Epub 2020 Nov 11.
3
Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.识别肝癌且极低失访风险的肝移植候选人:对当前器官分配政策的影响。
Liver Transpl. 2013 Dec;19(12):1343-53. doi: 10.1002/lt.23753.
4
Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.同型半胱氨酸:甲胎蛋白阴性肝细胞癌肝移植的新型预后生物标志物。
Cancer Biomark. 2020;29(2):197-206. doi: 10.3233/CBM-201545.
5
Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.重新调整肝细胞癌患者的治疗方法:肝癌肝移植相关风险的纵向评估(HALTHCC)可改善消融后等待策略。
Hepatology. 2018 Oct;68(4):1448-1458. doi: 10.1002/hep.29907.
6
Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.总肿瘤体积和甲胎蛋白联合用于选择肝癌肝移植候选者:前瞻性验证。
Hepatology. 2015 Jul;62(1):158-65. doi: 10.1002/hep.27787. Epub 2015 Apr 22.
7
AFP score and metroticket 2.0 perform similarly and could be used in a "within-ALL" clinical decision tool.甲胎蛋白(AFP)评分与地铁票2.0表现相似,可用于“ALL内部”的临床决策工具中。
JHEP Rep. 2022 Dec 5;5(2):100644. doi: 10.1016/j.jhepr.2022.100644. eCollection 2023 Feb.
8
Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.肝癌患者与非肝癌患者的终末期肝病模型评分增加导致等待名单死亡率差异增大。
Liver Transpl. 2012 Apr;18(4):434-43. doi: 10.1002/lt.23394.
9
AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study.AFP-L3 和 DCP 比 AFP 更能预测 HCC 患者在等待肝移植过程中的 dropout 率:一项前瞻性研究的结果。
Liver Transpl. 2023 Oct 1;29(10):1041-1049. doi: 10.1097/LVT.0000000000000149. Epub 2023 Apr 27.
10
Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance.比较公共医疗保险与私人医疗保险患者的肝癌肝移植候补名单结果。
JAMA Netw Open. 2019 Aug 2;2(8):e1910326. doi: 10.1001/jamanetworkopen.2019.10326.

引用本文的文献

1
Laparoscopic Microwave Ablation and Salvage Liver Transplantation in Patients with Hepatocellular Carcinoma.肝细胞癌患者的腹腔镜微波消融术与补救性肝移植
Cancers (Basel). 2025 Jul 4;17(13):2248. doi: 10.3390/cancers17132248.